Barclays lowered the firm’s price target on Cellectis (CLLS) to $4 from $5 and keeps an Overweight rating on the shares. The company’s Q1 was largely incremental with key pipeline programs on track, the analyst tells investors in a research note. The firm says Cellectis has a cash runway into the second half of 2027.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLLS: